A multi-center controlled study of rapid hepatitis B vaccination using a novel triple antigen recombinant vaccine

Michael D. Young, M. H. Rosenthal, Brian Dickson, Wei Du, Willis C. Maddrey

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Hepatitis B vaccines have been available for 20 years, however, the disease still remains a global problem. Clearly, the protection of at-risk groups could be improved if a more potent vaccine with a shorter vaccination regimen were available. Hepacare® is new recombinant vaccine, which contains three of the surface antigens of the HB virus and has higher immunogenicity than present single antigen (HBsAg only) vaccines. This study evaluates the potential for developing seroprotection rapidly and the viability of a 1 month/two dose regimen. A total of 400 adult subjects were vaccinated using either the present accelerated 2 month/three dose regimen of Engerix-B® or a 1 month/two dose regimen of a novel triple antigen vaccine (Hepacare®). Both vaccines were well tolerated. Four weeks after a single dose, the seroprotective rates for Engerix-B® and the triple antigen vaccine were 5 and 17%, respectively. By month 2, 4 weeks after two doses of vaccine, it was 38 and 61%. Finally by month 3, 4 weeks after a third dose of Engerix-B® or placebo, respectively, the seroprotection rates were 71 and 82%. The geometric mean titres (GMTs), of these responders was then 119 and 120 IU/l, respectively. Both vaccines were well tolerated. At all points up to and including 3 months after beginning vaccination, the novel 1 month/two dose regimen of Hepacare® was significantly more effective in producing seroporotective titres than the 2 month/three dose regimen of Engerix-B® (P=0.001).

Original languageEnglish (US)
Pages (from-to)3437-3443
Number of pages7
JournalVaccine
Volume19
Issue number25-26
DOIs
StatePublished - May 14 2001

Fingerprint

Synthetic Vaccines
hepatitis B
recombinant vaccines
Hepatitis B
Vaccination
Vaccines
vaccination
vaccines
antigens
Antigens
dosage
Hepatitis B Vaccines
Surface Antigens
Hepatitis B Surface Antigens
risk groups
surface antigens
placebos
Placebos
Viruses
immune response

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

A multi-center controlled study of rapid hepatitis B vaccination using a novel triple antigen recombinant vaccine. / Young, Michael D.; Rosenthal, M. H.; Dickson, Brian; Du, Wei; Maddrey, Willis C.

In: Vaccine, Vol. 19, No. 25-26, 14.05.2001, p. 3437-3443.

Research output: Contribution to journalArticle

Young, Michael D. ; Rosenthal, M. H. ; Dickson, Brian ; Du, Wei ; Maddrey, Willis C. / A multi-center controlled study of rapid hepatitis B vaccination using a novel triple antigen recombinant vaccine. In: Vaccine. 2001 ; Vol. 19, No. 25-26. pp. 3437-3443.
@article{3b10187d6fb041ab8c0ce1d64e3d3dbb,
title = "A multi-center controlled study of rapid hepatitis B vaccination using a novel triple antigen recombinant vaccine",
abstract = "Hepatitis B vaccines have been available for 20 years, however, the disease still remains a global problem. Clearly, the protection of at-risk groups could be improved if a more potent vaccine with a shorter vaccination regimen were available. Hepacare{\circledR} is new recombinant vaccine, which contains three of the surface antigens of the HB virus and has higher immunogenicity than present single antigen (HBsAg only) vaccines. This study evaluates the potential for developing seroprotection rapidly and the viability of a 1 month/two dose regimen. A total of 400 adult subjects were vaccinated using either the present accelerated 2 month/three dose regimen of Engerix-B{\circledR} or a 1 month/two dose regimen of a novel triple antigen vaccine (Hepacare{\circledR}). Both vaccines were well tolerated. Four weeks after a single dose, the seroprotective rates for Engerix-B{\circledR} and the triple antigen vaccine were 5 and 17{\%}, respectively. By month 2, 4 weeks after two doses of vaccine, it was 38 and 61{\%}. Finally by month 3, 4 weeks after a third dose of Engerix-B{\circledR} or placebo, respectively, the seroprotection rates were 71 and 82{\%}. The geometric mean titres (GMTs), of these responders was then 119 and 120 IU/l, respectively. Both vaccines were well tolerated. At all points up to and including 3 months after beginning vaccination, the novel 1 month/two dose regimen of Hepacare{\circledR} was significantly more effective in producing seroporotective titres than the 2 month/three dose regimen of Engerix-B{\circledR} (P=0.001).",
author = "Young, {Michael D.} and Rosenthal, {M. H.} and Brian Dickson and Wei Du and Maddrey, {Willis C.}",
year = "2001",
month = "5",
day = "14",
doi = "10.1016/S0264-410X(01)00054-8",
language = "English (US)",
volume = "19",
pages = "3437--3443",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "25-26",

}

TY - JOUR

T1 - A multi-center controlled study of rapid hepatitis B vaccination using a novel triple antigen recombinant vaccine

AU - Young, Michael D.

AU - Rosenthal, M. H.

AU - Dickson, Brian

AU - Du, Wei

AU - Maddrey, Willis C.

PY - 2001/5/14

Y1 - 2001/5/14

N2 - Hepatitis B vaccines have been available for 20 years, however, the disease still remains a global problem. Clearly, the protection of at-risk groups could be improved if a more potent vaccine with a shorter vaccination regimen were available. Hepacare® is new recombinant vaccine, which contains three of the surface antigens of the HB virus and has higher immunogenicity than present single antigen (HBsAg only) vaccines. This study evaluates the potential for developing seroprotection rapidly and the viability of a 1 month/two dose regimen. A total of 400 adult subjects were vaccinated using either the present accelerated 2 month/three dose regimen of Engerix-B® or a 1 month/two dose regimen of a novel triple antigen vaccine (Hepacare®). Both vaccines were well tolerated. Four weeks after a single dose, the seroprotective rates for Engerix-B® and the triple antigen vaccine were 5 and 17%, respectively. By month 2, 4 weeks after two doses of vaccine, it was 38 and 61%. Finally by month 3, 4 weeks after a third dose of Engerix-B® or placebo, respectively, the seroprotection rates were 71 and 82%. The geometric mean titres (GMTs), of these responders was then 119 and 120 IU/l, respectively. Both vaccines were well tolerated. At all points up to and including 3 months after beginning vaccination, the novel 1 month/two dose regimen of Hepacare® was significantly more effective in producing seroporotective titres than the 2 month/three dose regimen of Engerix-B® (P=0.001).

AB - Hepatitis B vaccines have been available for 20 years, however, the disease still remains a global problem. Clearly, the protection of at-risk groups could be improved if a more potent vaccine with a shorter vaccination regimen were available. Hepacare® is new recombinant vaccine, which contains three of the surface antigens of the HB virus and has higher immunogenicity than present single antigen (HBsAg only) vaccines. This study evaluates the potential for developing seroprotection rapidly and the viability of a 1 month/two dose regimen. A total of 400 adult subjects were vaccinated using either the present accelerated 2 month/three dose regimen of Engerix-B® or a 1 month/two dose regimen of a novel triple antigen vaccine (Hepacare®). Both vaccines were well tolerated. Four weeks after a single dose, the seroprotective rates for Engerix-B® and the triple antigen vaccine were 5 and 17%, respectively. By month 2, 4 weeks after two doses of vaccine, it was 38 and 61%. Finally by month 3, 4 weeks after a third dose of Engerix-B® or placebo, respectively, the seroprotection rates were 71 and 82%. The geometric mean titres (GMTs), of these responders was then 119 and 120 IU/l, respectively. Both vaccines were well tolerated. At all points up to and including 3 months after beginning vaccination, the novel 1 month/two dose regimen of Hepacare® was significantly more effective in producing seroporotective titres than the 2 month/three dose regimen of Engerix-B® (P=0.001).

UR - http://www.scopus.com/inward/record.url?scp=0035858124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035858124&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(01)00054-8

DO - 10.1016/S0264-410X(01)00054-8

M3 - Article

C2 - 11348708

AN - SCOPUS:0035858124

VL - 19

SP - 3437

EP - 3443

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 25-26

ER -